바이넥스

053030KOSDAQ의약품 제조업

37.3 / 100

Reference Date: 2026-06-10

Financial Score7.0 / 40

News Sentiment16.3 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Plunged 24.0% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Bionex is a biopharmaceutical CDMO company that produces chemical pharmaceuticals at its Busan factory and expanded production capacity threefold with a new facility in 2023. Its chemical business unit focuses on ointments and eye drops, securing market share with proprietary products, while biopharmaceutical CDMO services accounted for 46.72% of revenue in 2025. The company has established cGMP-compliant systems and passed global GMP inspections to grow as a global CDMO.

Number of Employees

791people

Average Salary

49.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 11.934.0Point

PBR

1.41Industry Average 0.891.0Point

1.6x industry avg (risky)

ROE

-1.78Industry Average 4.010.0Point

Well below industry avg

Debt Ratio

32.71Industry Average 12.430.0Point

2.6x industry avg (risky)

Trend 2023~20252.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲6.8% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼1482.8% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -6.2% (declining, 3yr)

Detailed News Sentiment

1 totalPositive 0Neutral 0Negative 1Average Sentiment Score 65

Negative
대우제약 임상시험 제재·리스테린 과징금…식약처 행정처분 잇따라
대우제약의 임상시험 규정 위반과 광고 집행 위반으로 인해 바이넥스의 신뢰도가 하락할 것으로 예상됩니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 8,100Won52-week high 18,49052-week low 8,100

1-month return0.0Point

1m -24.02% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-22
Neutral주식등의대량보유상황보고서(일반)2026-05-22
Neutral분기보고서 (2026.03)2026-05-15